4.8 Article

Phage anti-CBASS and anti-Pycsar nucleases subvert bacterial immunity

Journal

NATURE
Volume 605, Issue 7910, Pages 522-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41586-022-04716-y

Keywords

-

Funding

  1. Pew Biomedical Scholars programme
  2. Burroughs Wellcome Fund PATH programme, The Mathers Foundation
  3. Mark Foundation for Cancer Research
  4. Parker Institute for Cancer Immunotherapy
  5. National Institutes of Health [1DP2GM146250-01]
  6. European Research Council [ERC-AdG GA 101018520]
  7. Israel Science Foundation [ISF 296/21]
  8. Ernest and Bonnie Beutler Research Program of Excellence in Genomic Medicine
  9. Deutsche Forschungsgemeinschaft [SPP 2330, 464312965]
  10. Minerva Foundation
  11. Knell Family Center for Microbiology
  12. Cancer Research Institute Irvington Postdoctoral Fellowship [CRI3996]
  13. Minerva Foundation postdoctoral fellowship
  14. European Molecular Biology Organization postdoctoral fellowship [ALTF 946-2020]
  15. Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow (NIH) [F32GM133063, P30 GM124165, S10RR029205, S10OD021527]

Ask authors/readers for more resources

CBASS and Pycsar are bacterial defense systems against phages, and phages have developed anti-CBASS and anti-Pycsar proteins to counteract these defenses. These proteins degrade cyclic nucleotide signals that activate host immunity. Acb1 and Apyc1 are identified as founding members of distinct families of immune evasion proteins, and they block downstream effector activation, protecting phages from CBASS and Pycsar defense.
The cyclic oligonucleotide-based antiphage signalling system (CBASS) and the pyrimidine cyclase system for antiphage resistance (Pycsar) are antiphage defence systems in diverse bacteria that use cyclic nucleotide signals to induce cell death and prevent viral propagation(1,2). Phages use several strategies to defeat host CRISPR and restriction-modification systems(3-10), but no mechanisms are known to evade CBASS and Pycsar immunity. Here we show that phages encode anti-CBASS (Acb) and anti-Pycsar (Apyc) proteins that counteract defence by specifically degrading cyclic nucleotide signals that activate host immunity. Using a biochemical screen of 57 phages in Escherichia coli and Bacillus subtilis, we discover Acb1 from phage T4 and Apyc1 from phage SBSphiJ as founding members of distinct families of immune evasion proteins. Crystal structures of Acb1 in complex with 3'3'-cyclic GMP-AMP define a mechanism of metal-independent hydrolysis 3' of adenosine bases, enabling broad recognition and degradation of cyclic dinucleotide and trinucleotide CBASS signals. Structures of Apyc1 reveal a metal-dependent cyclic NMP phosphodiesterase that uses relaxed specificity to target Pycsar cyclic pyrimidine mononucleotide signals. We show that Acb1 and Apyc1 block downstream effector activation and protect from CBASS and Pycsar defence in vivo. Active Acb1 and Apyc1 enzymes are conserved in phylogenetically diverse phages, demonstrating that cleavage of host cyclic nucleotide signals is a key strategy of immune evasion in phage biology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available